Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

February 2, 2021

Conditions
Corona Virus Infection
Interventions
DRUG

NORS (Nitric Oxide Releasing Solution)

NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.

DRUG

NORS (Nitric Oxide Releasing Solution)

"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."

Trial Locations (5)

V5Y 3W2

BC Diabetes, Vancouver

H9R 4S3

LMC Manna, Pointe-Claire

G1N 4V3

Diex Recherche Québec, Québec

J6E 2B4

Diex Recherche Joliette, Saint-Charles-Borromée

J1L 0H8

Diex Recherche Sherbrooke, Sherbrooke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

Keyrus Life Science

NETWORK

lead

Sanotize Research and Development corp.

INDUSTRY

NCT04337918 - Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection | Biotech Hunter | Biotech Hunter